• Halozyme appointed David Ramsay as president, drug delivery, effective June 30, 2026.
• Role carries an enterprise-wide mandate to set strategy for drug delivery technologies, drive growth, lead business development, manage alliances.
• Ramsay reports to CEO Helen Torley.
• He served as interim CFO from March 23 to June 8, 2026, before Darren Snellgrove took over as CFO.
• Ramsay previously held multiple leadership posts at Halozyme, including CFO, later serving as CFO of Bonti until its 2018 sale to Allergan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606301602PR_NEWS_USPR_____LA95734) on June 30, 2026, and is solely responsible for the information contained therein.